Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies—oral, small molecule inhibitors targeting families of oncogenic mutations across genetically defined cancers. Its proprietary MAP drug discovery engine identifies and inhibits mutation-driven cancer proteins with selectivity and brain penetration. Key programs focus on EGFR-mutant non-small cell lung cancer and glioblastoma. The company aims to address resistance and expand targeted treatment options for patients with limited therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.